Hearing impairment

Late Effects of Childhood Cancer

Volumn , Issue , 2004, Pages 49-54

  Shearer, Patricia D ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 7044265151     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (51)

1. Stadnicki SW, Fleischman RW, Schaeppi U, Merriam P. Cisdichlorodiammine platinum (II) (NSC-119875): hearing loss and other toxic effects in rhesus monkeys. Cancer Chemother Rep 1975; 59:467-480
2. Nakai Y, Konishi K, Chang KC, et al. Ototoxicity of the anticancer drug cisplatin: an experimental study. Acta Otolaryngol (Stockholm) 1982; 93:227-232
3. Comis SD, Rhys-Evans PH, Osborne MP, et al. Early morphological and chemical changes induced by cisplatin in the guinea pig organ of Corti. J Laryngol Otol 1986; 100:1375-1383
4. Boheim K, Bichler E. Cisplatin-induced ototoxicity: audiometric findings and experimental cochlear pathology. Arch Otorhinolaryngol 1985; 242:1-6
5. Trump BF, Berezesky IK, Sato T, et al. Cell calcium, cell injury, and cell death. Environ Health Perspect 1984; 57:281-287
6. Brusilow SW, Gordes E. The mutual independence of the endolymphatic potential and the concentrations of sodium and potassium in endolymph. J Clin Invest 1973; 52:2517-2521
7. Altura BM, Altura BT, Gebrewold A, et al. Magnesium deficiency and hypertension: correlation between magnesium-deficient diets and microcirculatory changes in situ. Science 1984; 223:1315-1317
8. Brown RD. Ethacrynic acid and furosemide: possible cochlear sites and mechanisms of ototoxic action. Medikon 1975; 4:33-40
9. Joachims Z, Babisch W, Ising H, et al. Dependence of noiseinduced hearing loss upon perilymph magnesium concentration. J Acoust Soc Am 1983; 74:104-108
10. Blakley B, Gupta A, Myers S, Schwan MA. Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg 1994; 120:541-546
11. Todd W, Alvarado C, Brewer D. Cisplatin in children: hearing loss correlates with iris and skin pigmentation. J Laryngol Otol 1995; 109:926-929
12. Berg A, Spitzer J, Garvin J. Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoscope 1999; 109:1806-1814
13. Reddell R, Kefford R, Grant J, et al. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 1982; 66:19-23
14. McHaney V, Thibadoux M, Hayes A, Green A. Hearing loss in children receiving cisplatin chemotherapy. J Pediatr 1983; 102:314-317
15. McHaney V, Kovnar E, Meyer W, et al. Effects of radiation therapy and chemotherapy on hearing. In: Green DM, D’Angio GJ (eds) Late effects of treatment for childhood cancer. New York: Wiley-Liss, Inc., 1991:7-10
16. Schell M, McHaney V, Green A, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 1989; 7:754-760
17. Kretschmar C, Warren M, Lavally B, et al. Ototoxicity of preradiation cisplatin for children with central nervous system tumors. J Clin Oncol 1990; 8:1191-1198
18. Pasic T, Dobie R. Cis-platinum ototoxicity in children. Laryngoscope 1991; 101:985-991
19. Berlin C, Hood L, Hurley A, Wen H. Hearing aids: only for hearing impaired patients with abnormal otoacoustic emissions. In: Berlin CI (ed.) Hair cells and hearing aids. San Diego: Singular Publishing Group, 1996
20. Stengs C, Klis S, Huizing E, Smoorenburg G. Cisplatin-induced ototoxicity; electrophysiological evidence of spontaneous recovery in the albino guinea pig. Hear Res 1997; 111: 103-113.
21. Macdonald M, Harrison R, Wake M, et al. Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children. J Otolaryngol 1994; 23:151-159
22. Saito T, Saito H, Saito K, et al. Ototoxicity of carboplatin in guinea pigs. Auris Nasus Larynx 1989; 16:13-21
23. Taudy M, Syka J, Popelar J, Ulehlova L. Carboplatin and cisplatin ototoxicity in guinea pigs. Audiology 1992; 31:293-299
24. Freilich R, Kraus D, Budnick A, et al. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue. Med Pediatr Oncol 1996; 26:95-100
25. Parsons S, Neault M, Lehmann L, et al. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 1998; 22:669-674
26. Meyer W, Ayers D, McHaney V, et al. Ifosfamide and exacerbation of cisplatin-induced hearing loss. Lancet 1993; 341:754-755
27. Bajwa R, Price L, Roberts A, et al. Auditory function is unaffected by treatment with ifosfamide in children and adolescents. Med Pediatr Oncol 2000; 35:156
28. Hood L. Auditory neuropathy: what is it and what can we do about it? Hearing J 1998; 51:10-18
29. Amatuzzi M, Northrup C, Liberman M, et al. Selective inner hair cell loss in premature infants and cochlea pathological patterns from neonatal intensive care unit autopsies. Arch Otolaryngol Head Neck Surg 2001; 127:629-636
30. Sie K, Norton S. Changes in otoacoustic emissions and auditory brain stem response after cis-platinum exposure in gerbils. Otolaryngol Head Neck Surg 1997; 116:585-592
31. Littman T, Magruder A, Strother D. Monitoring and predicting ototoxic damage using distortion-product otoacoustic emissions: pediatric case study. J Am Acad Audiol 1998; 9:257-262
32. Allen G, Tiu C, Koike K, et al. Transient-evoked otoacoustic emissions in children after cisplatin chemotherapy. Otolaryngol Head Neck Surg 1998; 118:584-588
33. Saito T, Zhang Z, Manabe Y, et al. The effect of sodium thiosulfate on ototoxicity and pharmacokinetics after cisplatin treatment in guinea pigs. Eur Arch Otorhinolaryngol 1997; 254:281-286
34. Maduso R, Ruckenstein M, Leake F, et al. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 1997; 123:978-981
35. Gabaizadeh R, Staecker H, Lui W, et al. Protection of both auditory hair cells and auditory neurons from cisplatin induced damage. Acta Otolaryngol (Stockholm) 1997; 117:232-238
36. Campbell K, Rybak L, Meech R, Hughes L. D-Methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res 1996; 102:90-98
37. Rybak L, Husain K, Evenson L, et al. Protection by 4-methylthiobenzoic acid against cisplatin-induced ototoxicity: antioxidant system. Pharmacol Toxicol 1997; 81:173-179
38. Hensley M, Schuchter L, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17:3333-3355
39. Capizzi R, Oster W. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials. Int J Hematol 2000; 72:425-435
40. Santini V. Amifostine: chemotherapeutic and radiotherapeutic protective effects. Expert Opin Pharmacother 2001; 2: 479-489
41. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14:2101-2112.
42. Grau J, Estape J, Cuchi M, et al. Calcium supplementation and ototoxicity in patients receiving cisplatin. Br J Clin Pharmacol 1996; 42:233-235
43. Taylor C, Briggs A, Epner E, List A. Amifostine cytoprotection in an outpatient high-dose chemotherapy regimen for breast cancer [abstract]. Proc Am Soc Clin Oncol 1999; 18:137a
44. Brizel D, Wasserman T, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18:3339-3345
45. Yuhas J, Spellman J, Jordan S, et al. Treatment of tumors with the combination of WR-2721 and cisdichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer 1980; 42:574-585
46. Grdina D, Hunter N, Kataoka Y, et al. Chemoprotective doses of amifostine confer no cytoprotection to tumor nodules growing in the lungs of mice treated with cyclophosphamide. Semin Oncol 1999; 26(2 Suppl 7):22-27
47. Glover D, Glick J, Weiler C, et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987; 5:574-578.
48. Schiller J. High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer. Semin Oncol 1996; 23:78-82
49. Fouladi M, Koren G, Greenberg M, et al. Safety and monitoring guidelines of amifostine in the pediatric population: results of a phase I/II trial of ICE with amifostine. Clin Invest Med (Suppl) 1998; S8
50. Schuchter L, Glick J. The current status of WR-2721 (Amifostine): a chemotherapy and radiation therapy protector. Biol Ther Cancer 1993; 3:1-10
51. Glover D, Riley L, Carmichael K, et al. Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR2721 (a radioprotective and chemoprotective agent). N Engl J Med 1983; 309:1137-1141.